Troponin Elevations After Electroconvulsive Therapy: The Need for Caution - 19/08/11

Abstract |
Background |
Electroconvulsive therapy is used to treat patients with severe or resistant depression. Troponin elevations are associated with an adverse prognosis, and it is well known that central nervous system insults can cause biochemical evidence of cardiac injury. No study previously has studied this with electroconvulsive therapy.
Methods |
Patients scheduled for electroconvulsive therapy were enrolled. Clinical information, an electrocardiogram, and a baseline sample for cardiac troponin I and T (cTnI and cTnT) were obtained. Electroconvulsive therapy was done with standard techniques. Subsequently, electrocardiograms and additional samples were obtained. cTnT was measured with the Roche assay and cTnI with the Dade Stratus equipment. Values above the 99th percentile were considered abnormal.
Results |
Seventy patients completed the study. Four patients had elevated levels of cTn before treatment. In 3 patients, the elevations persisted. Four additional patients developed elevated cTn levels during electroconvulsive therapy. Two of the patients with cTn elevations died. No other events occurred during follow-up.
Conclusions |
Elevations of cTn occurred in 11.5% of patients treated with electroconvulsive therapy. Some of the elevations preceded therapy and some occurred during treatment. Given the adverse prognostic importance of cTn elevations in general, in addition to additional studies, an increased degree of medical scrutiny may be appropriate for this group of patients and for those receiving electroconvulsive therapy. © 2011 Elsevier Inc. All rights reserved.
El texto completo de este artículo está disponible en PDF.Keywords : Electroconvulsive therapy, Troponin
Esquema
| Funding: Supported in part by the small grants program through the Division of Cardiology at the Mayo Clinic, Rochester, Minnesota. |
|
| Conflict of Interest: Dr. Jaffe is at present or has been in the past a consultant to most of the major diagnostic companies, including those that make the troponin assays used in this study. |
|
| Authorship: All authors had access to the data and played a role in writing this manuscript. |
|
| Dr. Matthew W. Martinez is now at the Lehigh Valley Health Network, 1250 S Cedar Crest Blvd., Suite 300, Allentown, PA 18103. |
Vol 124 - N° 3
P. 229-234 - mars 2011 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?
